Elicio Therapeutics, Inc. (ELTX) Key Metrics
ELTX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $42.3M
- Enterprise value
- $39.7M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 6.2
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.98
ELTX key metrics, 2012–2025
Fiscal year ended December 31, 2025 · U.S. dollarsELTX valuation Price multiples at each fiscal year-end price.
Free cash flow yield+29.4 pts
−30.3%
2025 · hover or tap a bar for each year
20122025
ELTX returns How much profit the business earns on the capital it uses.
Return on assets+41.2 pts
−146.5%
2025 · hover or tap a bar for each year
20122025
Asset turnover
0.00
2025 · hover or tap a bar for each year
20122025
ELTX per-share figures Results divided by the shares outstanding at year-end.
Revenue per share
$0.00
2025 · hover or tap a bar for each year
20122025
Earnings per share
−$2.58
2025 · hover or tap a bar for each year
20122025
Free cash flow per share
−$2.41
2025 · hover or tap a bar for each year
20122025
Book value per share
$0.11
2025 · hover or tap a bar for each year
20122025
Shares outstanding+25.5%
15.3M
2025 · hover or tap a bar for each year
20122025
ELTX financial health Debt, liquidity and how easily interest is covered.
Debt / equity
8.87
2025 · hover or tap a bar for each year
20122025
Net debt−$12.5M
−$4.1M
2025 · hover or tap a bar for each year
20122025
Current ratio+32.6%
2.38
2025 · hover or tap a bar for each year
20122025
Interest coverage
-33.3
2025 · hover or tap a bar for each year
20122025
Debt / assets−39.3%
0.56
2025 · hover or tap a bar for each year
20122025
ELTX efficiency & capital use Working capital cycle and where the cash goes.
Days payables outstanding−561 days
277 days
2025 · hover or tap a bar for each year
20122025
ELTX valuation history
Fiscal year-endToday10-year median
ELTX returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ELTX debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ELTX cash returned to shareholders
DividendsBuybacksFree cash flow
ELTX price vs earnings per share
Share price at year-endEPS (right axis)
ELTX key metrics
2012–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $121.9M | $62.2M | — | — | — | — | — | — | — | — |
| Enterprise value | $117.8M | $70.7M | — | — | — | — | — | — | — | — |
| Price / book | 74.5 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −32.5% | −83.4% | — | — | — | — | — | — | — | — |
| Free cash flow yield | −30.3% | −59.7% | — | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | 0.9% | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $7.96 | $5.10 | $8.34 | $8.12 | $29.00 | — | — | — | — | — |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | — | — | — | $0.35 | $0.18 | — | — | — |
| Earnings per share | −$2.58 | −$4.25 | — | — | — | −$9.83 | −$4.99 | — | — | — |
| Operating cash flow per share | −$2.41 | −$3.04 | — | — | — | −$2.81 | −$3.02 | — | — | — |
| Free cash flow per share | −$2.41 | −$3.04 | — | — | — | −$2.81 | −$3.05 | — | — | — |
| Cash per share | $1.21 | $1.44 | — | — | — | $4.25 | $0.68 | — | — | — |
| Book value per share | $0.11 | −$0.93 | — | — | — | −$11.10 | −$2.28 | — | — | — |
| Tangible book value per share | $0.11 | −$0.93 | — | — | — | −$11.10 | −$2.28 | — | — | — |
| Capex per share | $0.00 | $0.01 | — | — | — | $0.01 | $0.03 | — | — | — |
| Debt per share | $0.95 | $2.13 | — | — | — | $10.43 | $1.32 | — | — | — |
| Shares outstanding | 15.3M | 12.2M | — | — | — | 8.2M | 8.2M | — | — | — |
| Change in shares outstanding | +25.5% | — | — | — | — | 0.0% | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | −347.0% | −62.4% | — | — | — | −188.4% | 31.2% | 18.0% |
| Return on invested capital (ROIC) | — | — | −403.6% | −623.7% | — | — | — | — | −5.2% | −6.1% |
| Return on assets (ROA) | −146.5% | −187.6% | −141.3% | −47.3% | −36.7% | −270.5% | −211.1% | −106.3% | 5.7% | 2.8% |
| Return on tangible assets | −153.0% | −184.2% | −129.7% | −124.5% | −27.4% | −169.2% | −342.1% | −75.2% | 5.7% | 2.8% |
| Free cash flow margin | — | — | — | — | −86.4% | −796.1% | — | −199.1% | 28.5% | 13.9% |
| Income quality (OCF / net income) | — | — | — | — | — | — | — | — | 2.99 | 3.47 |
| Financial health | ||||||||||
| Total debt | $14.5M | $26.0M | $6.9M | $7.5M | $4.7M | $85.0M | $10.8M | — | $5.3M | $5.4M |
| Cash & short-term investments | $18.6M | $17.6M | $12.9M | $7.8M | $88.8M | $34.6M | $5.6M | $25.5M | $2.1M | $1.4M |
| Net debt | −$4.1M | $8.4M | −$6.0M | −$316,000 | −$84.1M | $50.4M | $5.2M | −$25.5M | $3.3M | $4.0M |
| Debt / equity | 8.87 | — | 0.61 | 0.84 | 0.06 | — | — | — | 2.27 | 3.18 |
| Debt / assets | 0.56 | 0.92 | 0.25 | 0.33 | 0.05 | 1.80 | 0.91 | — | 0.48 | 0.49 |
| Net debt / EBITDA | — | — | — | — | — | — | — | — | 52.24 | 2.05 |
| Current ratio | 2.38 | 1.80 | 1.68 | 1.56 | 8.08 | 0.38 | 0.23 | 3.49 | 2.28 | 1.87 |
| Quick ratio | 2.38 | 1.80 | 1.68 | 0.95 | 8.06 | 0.42 | 0.23 | 3.49 | 2.28 | 1.87 |
| Interest coverage | -33.3 | -98.9 | -33.8 | -6.6 | -44.8 | -6.2 | — | — | -1.3 | -1.4 |
| Working capital | $11.2M | $9.2M | $6.6M | $3.8M | $80.0M | −$67.1M | −$20.5M | $18.3M | $1.5M | $959,801 |
| Invested capital | −$2.4M | −$2.9M | $5.4M | $8.6M | −$2.6M | −$40.0M | −$13.4M | −$6.6M | $5.6M | $5.7M |
| Tangible asset value | $1.6M | −$11.3M | $11.4M | $8.9M | $81.5M | −$90.4M | −$18.6M | $18.9M | $4.5M | $4.2M |
| Net current asset value | −$4.9M | −$18.8M | $575,000 | −$3.0M | $76.2M | −$97.5M | −$24.4M | $18.0M | −$4.0M | −$4.7M |
| Graham net-net per share | −$0.37 | −$1.79 | — | — | — | −$12.48 | −$3.02 | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | $549,000 | $150,000 | $0 | — | $36,000 | $375,000 | — | — | — |
| Capex / revenue | — | — | — | — | 1.9% | 1.4% | 16.3% | 0.0% | 0.3% | 0.7% |
| Capex / operating cash flow | — | — | — | — | — | — | — | — | 0.9% | 4.5% |
| Capex / depreciation | 0.01 | 0.07 | 0.06 | 0.62 | 2.09 | 0.07 | 0.49 | 0.00 | 0.04 | 0.10 |
| Stock-based compensation / revenue | — | — | — | — | 2.2% | 10.6% | 9.8% | — | — | — |
| R&D / revenue | — | — | — | — | 171.7% | 1,350.0% | 2,003.2% | 227.1% | 3.0% | — |
| SG&A / revenue | — | — | — | — | 26.6% | 104.2% | 188.2% | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | — | 37.4 | 344.7 | 67.1 | 26.9 | 29.6 | 29.0 |
| Days of inventory on hand | — | — | — | 761.2 | -655.5 | -470.3 | -20.5 | — | 0.0 | — |
| Days payables outstanding | 276.7 | 837.7 | 1,119.0 | 1,297.5 | 1,521.5 | 1,688.2 | 1,891.3 | 274.5 | 14.2 | 20.8 |
| Cash conversion cycle (days) | — | — | — | — | -2,139.6 | -1,813.8 | -1,844.7 | -247.7 | 15.4 | 8.2 |
| Receivables turnover | — | — | — | — | 9.75 | 1.06 | 5.44 | 13.59 | 12.35 | 12.57 |
| Payables turnover | 1.32 | 0.44 | 0.33 | 0.28 | 0.24 | 0.22 | 0.19 | 1.33 | 25.68 | 17.53 |
| Inventory turnover | — | — | — | 0.48 | — | — | — | — | 3,173,478.00 | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.39 | 0.10 | 0.08 | 0.21 | 0.60 | 0.66 |
| Average receivables | — | — | — | — | $2.9M | $2.7M | $273,500 | $296,381 | $533,070 | $580,378 |
| Average payables | $855,000 | $2.7M | $3.6M | $3.8M | $5.1M | $8.4M | $5.9M | $285,811 | $123,569 | $209,516 |
| Average inventory | — | — | — | $2.2M | −$2.2M | −$2.3M | −$63,707 | — | $1 | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ELTX's annual financial statements (latest annual report filed March 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ELTX valuation and financial ratios
It ended the year with $14.5 million of debt and $18.6 million in cash and short-term investments, a net cash position of $4.1 million.
See the ELTX income statement, the ELTX chart for price history, or the ELTX stock overview for the latest quote and news.
ELTX key metrics FAQ
How much debt does Elicio Therapeutics have?
Elicio Therapeutics had total debt of $14.5 million at the end of fiscal 2025, a debt-to-equity ratio of 8.87 and more cash than debt.
What is Elicio Therapeutics's free cash flow yield?
Elicio Therapeutics generated -$37.0 million of free cash flow in fiscal 2025, a free cash flow yield of −30.3% on its market value at year-end ($121.9 million).
What is Elicio Therapeutics's current ratio?
Elicio Therapeutics's current ratio was 2.38 at the end of fiscal 2025: current assets were 2.38 times current liabilities.